S2Medical AB - Product Pipeline Analysis | Update - 2018


Summary:

S2Medical AB (S2Medical) is a research intensive medtech company that designs, develops and markets wound dressings products to treat burns and chronic ulcers. The company product portfolio includes wound dressing patches, blood stilling synthetic epithelium dressing to control capillary bleeding, and skin grafting tools for grafting the damaged skin. It manufactures Eiratex, a biosynthetic polymer that mimics collagen at a nano level, which provides biocompatibility and conformability. S2Medical offers polymer of sugar molecules in Eiratex that provides strength, breathability and transparency, and promotes wound healing. The company conducts research to develop wound care dressings using antimicrobial peptides that control infection at the wound site. S2Medical is headquartered in Linkoping, Sweden.

This report is a source for data, analysis, and actionable intelligence on the company's portfolio of pipeline products. The report provides key information about the company, its major products and brands. 

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.


                                                               Get Free Sample Report:

                                                       S2Medical AB - Product Pipeline Analysis


Scope:

- The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
- The report analyzes all pipeline products in development for the company S2Medical AB
- The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
- The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
- The report provides detailed description of products in development, technical specification and functions
- The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.

Reasons To Buy:

- Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
- Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
- To formulate effective Research & Development strategies
- Develop market-entry and market expansion strategies
- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline 
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop competition strategies by identifying the status and likely launch of the competitors pipeline products through review of the clinical trials, stage and of development, etc
- Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio

Note: Some sections may be missing if data is unavailable for the company

                                                                      Browse Full Report:

                                            S2Medical AB - Product Pipeline Analysis, 2018 Update


We have a huge database of  Healthcare-Medical search reports  If you have any special

Comments

Popular posts from this blog

CVX – Tigris Offshore Oil Field Development – Gulf of Mexico - Project Profile

Varun Beverages Zimbabwe( VBZ ) – Harare Bottling Plant - Project Profile, zimbabwe

India Oilfield Services Market By Application, By Service Competition | Forecast & Opportunities, 2013 - 2027